Shenqi Fuzheng Injection impairs bile duct ligation-induced cholestatic liver injury in vivo

Biosci Rep. 2019 Jan 25;39(1):BSR20180787. doi: 10.1042/BSR20180787. Print 2019 Jan 31.

Abstract

Background and aim: The aim of the present study sought to determine the protective function of Shenqi Fuzheng Injection (SFI) in cholestatic liver injury.

Methods: Cholestatic liver injury was induced in a 7-day bile duct-ligated (BDL) rat model. Rats were divided into three groups that were comprised of: (1) Sham; (2) BDL model; and (3) SFI treatment. The sham and BDL groups were treated with an appropriate volume of 0.9% sodium chloride as the vehicle, and the SFI group was administered SFI at a dose of 20 ml/kg/day, via tail vein injection.

Results: SFI significantly (all at P<0.01) decreased the levels of serum aspartate aminotransferase and alanine aminotransferase as compared with the BDL group, which was associated with reduced severity of inflammatory cell infiltration and hepatic damage. Moreover, SFI significantly decreased the levels of hepatic interleukin-6 (P<0.01), tumor necrosis factor-α (P=0.041), and malondialdehyde (P=0.026), and significantly increased the levels of total superoxide dismutase (P<0.01), and the GSH/GSSG ratio (P=0.041) in the liver. Western blot analysis showed that SFI increased PPAR-γ expression; however, SFI treatment decreased cyclooxygenase-2 (COX-2) expression and the phosphorylation of NF-κBp65.

Conclusions: These data demonstrated that SFI attenuated both inflammation and oxidative stress, and disrupted cholestatic liver injury. The involved mechanism was dependent, at least in part, on regulating PPAR-γ, COX-2, and NF-κBp65 expression.

Keywords: Shenqi Fuzheng Injection; bile duct ligation; cholestatic liver injury; inflammation; oxidative stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Bile Ducts / pathology
  • Bile Ducts / surgery
  • Cholestasis / drug therapy*
  • Cholestasis / etiology
  • Cholestasis / pathology
  • Disease Models, Animal
  • Drugs, Chinese Herbal / administration & dosage*
  • Gene Expression Regulation / drug effects
  • Humans
  • Ligation / adverse effects
  • Lipid Peroxidation / drug effects
  • Liver / drug effects*
  • Liver / pathology
  • Liver Diseases / drug therapy*
  • Liver Diseases / etiology
  • Liver Diseases / pathology
  • Oxidative Stress / drug effects
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha / genetics
  • Rats
  • Transcription Factor RelA / genetics

Substances

  • Drugs, Chinese Herbal
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Ppargc1a protein, rat
  • Rela protein, rat
  • Transcription Factor RelA
  • shenqi fuzheng